Immunocore Reports Q3 Results, KIMMTRAK Revenue Reaches $102.2 Million
KIMMTRAK net revenues were $102.2 million in Q3 2026 and $324.8 million in the first nine months, up 10% year over year. Immunocore also said its Phase 3 TEBE-AM trial completed target enrollment of 540.
Story updates
02:02:11 PM UTC
SquawkNews
KIMMTRAK net sales were $102.2M in Q3 2026 versus $103.7M a year earlier, and $324.8M for nine months versus $295.5M. Q3 net loss was $14.2M versus $0.2M; the company expects to pay approximately $120M in sales-related rebates in Q4 2026.Material DetailsContext by AI AnalystThis is a quarterly upda…
02:03:35 PM UTC
SquawkNews
Immunocore reported third-quarter 2026 revenue of $102.2 million, down from $103.7 million a year earlier, and a net loss of $14.2 million. Revenue for the first nine months rose to $324.8 million from $295.5 million. The company also reported progress across its melanoma, infectious disease and au…
KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to datePhase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540…